Needham Downgrades ResMed to Hold, Maintains $236 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has downgraded ResMed (NYSE:RMD) from Buy to Hold, while maintaining a price target of $236.
September 04, 2024 | 9:58 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst Mike Matson downgraded ResMed from Buy to Hold, maintaining a $236 price target. This downgrade may indicate a neutral outlook on the stock's short-term performance.
The downgrade from Buy to Hold suggests that the analyst sees limited upside potential in the short term, despite maintaining the price target. This could lead to a neutral impact on the stock price as investors may adjust their expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100